Skip to main content
logo
Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
168.62
+3.11 (1.88%)
At close: Feb 27, 2026, 4:00 PM EST
168.62
0.00 (0.00%)
After-hours: Feb 27, 2026, 5:20 PM EST

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Innovative Medicines Revenue
54.53B50.32B
Innovative Medicines Revenue Growth
8.38%12.73%
Revenue (Other)
2.14B1.41B
Revenue (Total)
56.67B51.72B
Revenue (Total) Growth
9.57%10.85%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue (Post-Q2 2023 Reporting)
23.33B21.15B
United States Revenue (Post-Q2 2023 Reporting) Growth
10.33%17.75%
Europe Revenue (Post-Q2 2023 Reporting)
16.73B15.56B
Europe Revenue (Post-Q2 2023 Reporting) Growth
7.53%3.73%
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting)
10.80B10.02B
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) Growth
7.74%7.66%
Canada and Latin America Revenue (Post-Q2 2023 Reporting)
3.68B3.59B
Canada and Latin America Revenue (Post-Q2 2023 Reporting) Growth
2.28%13.13%
Revenue (Other)
2.14B1.41B
Revenue (Total)
56.67B51.72B
Revenue (Total) Growth
9.57%10.85%

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Cardiovascular, Renal And Metabolic Revenue
8.96B8.58B
Cardiovascular, Renal And Metabolic Revenue Growth
4.47%34.21%
Immunology Revenue
10.29B9.29B
Immunology Revenue Growth
10.76%19.17%
Neuroscience Revenue
5.99B4.75B
Neuroscience Revenue Growth
26.17%30.10%
Oncology Revenue
16.83B14.30B
Oncology Revenue Growth
17.72%11.25%
Established Brands Revenue
12.46B13.40B
Established Brands Revenue Growth
-7.04%-9.15%
Revenue (Total)
56.67B51.72B
Revenue (Total) Growth
9.57%10.85%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Cosentyx Revenue
6.67B6.14B
Cosentyx Revenue Growth
8.58%23.31%
Gilenya Revenue
-552.00M
Gilenya Revenue Growth
--40.32%
Entresto Revenue
7.75B7.82B
Entresto Revenue Growth
-0.95%29.61%
Tasigna Revenue
1.10B1.67B
Tasigna Revenue Growth
-33.93%-9.58%
Lucentis Revenue
643.00M1.04B
Lucentis Revenue Growth
-38.41%-29.22%
Updated Feb 4, 2026. Data Source: Fiscal.ai.